VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) (“Liberty Gold” or the “Company”) announces that it has entered into a definitive share purchase agreement (the “Agreement”) to sell the issued and outstanding shares of its subsidiary, Speciality American Metals Inc., that owns the Goldstrike Project located in southern Utah (“Goldstrike”), to Heliostar Metals Ltd. (“Heliostar”) for US$72.5 million in total consideration (the “Transaction”). The Tran ...

Core Viewpoint - Skyline Builders Group Holding Limited announced a brokered private placement of senior unsecured convertible notes and preferred shares, raising approximately $17,175,000 before expenses [1]. Group 1: Private Placement Details - The private placement includes the issuance of senior unsecured convertible notes and 250,000 class B preferred shares [1]. - Approximately $16,575,000 of the notes were issued under a Regulation D offering to US investors, while about $600,000 of preferred shares were issued under a Regulation S offering to non-US investors [2]. - Each note and preferred share is convertible into class A ordinary shares at a conversion price of $2.40, with anti-dilution adjustments ensuring a minimum conversion price of $1.50 [1]. Group 2: Registration and Closing - The company will enter into Registration Rights Agreements to file a registration statement with the SEC within 60 business days for the resale of the underlying class A ordinary shares [3]. - The private placement is expected to close on or about March 24, 2026, pending customary closing conditions [4]. Group 3: Company Overview - Skyline Builders Group Holding Limited operates as a public works contractor in Hong Kong, focusing on civil engineering works such as roads and drainage [7]. - The company primarily undertakes public sector infrastructure projects and private sector residential and commercial developments [7].

Core Viewpoint - EZCORP, Inc. is set to host its Annual Meeting of Stockholders on March 26, 2026, at 9:00 a.m. Central Time, providing an opportunity for investors to engage with the company [1]. Group 1: Company Overview - EZCORP is a leading provider of pawn transactions in the United States and Latin America, established in 1989 [3]. - The company also sells pre-owned and recycled merchandise, primarily from collateral forfeited from pawn lending operations and merchandise purchased from customers [3]. - EZCORP focuses on satisfying the short-term cash needs of consumers who are cash and credit constrained, emphasizing an industry-leading customer experience [3]. - The company is publicly traded on NASDAQ under the symbol EZPW and is a member of the S&P 1000 Index and Nasdaq Composite Index [3]. Group 2: Investor Relations - EZCORP's Annual Report on Form 10-K for fiscal 2025 has been filed with the Securities and Exchange Commission and is available in the Investor Relations section of the company's website [2]. - Stockholders can request a paper copy of the report free of charge by contacting the investor relations team [2].

Core Insights - The company, NovaBay Pharmaceuticals, Inc., will change its name to Stablecoin Development Corporation and its ticker symbol to SDEV, effective April 3, 2026, reflecting its strategic focus on the stablecoin economy [2][19] - The company has acquired approximately 2.06 billion SKY tokens, representing about 8.78% of the total supply of SKY, and has earned approximately 26.6 million SKY tokens in cumulative staking rewards [8][6] - The company aims to establish itself as a leading public market vehicle for accessing cash flows within the growing stablecoin economy, emphasizing the importance of stablecoins in digital finance [3][13] Private Placement Overview - On January 16, 2026, the company entered into a Securities Purchase Agreement with several investors, resulting in gross proceeds of approximately $134 million through the issuance of pre-funded warrants for 167,539,226 shares of common stock [4] - The company received approximately 943,599,689 SKY tokens valued at about $58 million as part of the private placement transaction, along with $25 million in cash and $51 million in stablecoins [7] Staking and Acquisitions - The company has actively participated in staking activities, generating approximately 26.6 million SKY tokens in rewards since the commencement of its on-chain staking [6][15] - Following the private placement, the company acquired approximately 1.09 billion additional SKY tokens on the open market at an average price of about $0.065 per token [7][8] On-Chain Holding Company Framework - The company has adopted an on-chain holding company framework focused on long-duration participation in digital asset ecosystems, specifically the Sky protocol [5][12] - This framework allows the company to hold protocol-aligned digital assets for extended periods while maintaining the flexibility to monetize holdings for corporate purposes [12] Institutional Participation and Market Dynamics - The participation of Tether Investments in the private placement indicates growing institutional interest in stablecoin-enabled financial infrastructure [14] - The company has implemented trading covenants to promote stable market dynamics, limiting daily sales by purchasers to 10% of the 30-day average trading volume [11] Context of Stablecoins - The company views stablecoins as a critical component of the global digital financial infrastructure, with expanding use cases in settlement, payments, and yield generation [13] - The rise of yield-bearing stablecoins is seen as a significant evolution in digital finance, providing new opportunities for savings and capital formation [13]

Core Insights - Biodexa Pharmaceuticals has launched a Global Early Access Program for eRapa, aimed at providing this investigational treatment to patients with Familial Adenomatous Polyposis (FAP) through a partnership with Tanner Pharma Group [1][2][3] Group 1: Company Overview - Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative treatments for gastrointestinal cancers [1] - The company’s lead development programs include eRapa for FAP and Non-Muscle Invasive Bladder Cancer, MTX240 for Gastrointestinal Stromal Tumors, and tolimidone for type 1 diabetes [7] Group 2: eRapa Details - eRapa is an oral capsule formulation of rapamycin, an mTOR inhibitor, which plays a significant role in cellular metabolism, growth, and proliferation [4][8] - The drug has received Orphan Designation in the US, with plans to seek similar designation in Europe, and is based on the rationale that mTOR is over-expressed in FAP polyps [3][4] Group 3: Early Access Program - The Early Access Program will allow clinicians globally to prescribe eRapa to appropriate FAP patients, subject to local regulations and funding availability [2] - Biodexa aims to generate Real World Data to enhance understanding of the challenges faced by FAP patients [2] Group 4: Clinical Trials - A double-blind, placebo-controlled Phase 3 trial for eRapa is planned, involving 30 clinical sites across the US and Europe, with an enrollment target of 168 patients in a 2:1 randomization [4] - The Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas [4] Group 5: Tanner Pharma Group - Tanner Pharma Group is a specialist pharmaceutical services provider that focuses on improving global access to medicines, supporting manufacturers in providing compliant access to innovative treatments [5]

Core Viewpoint - YSX Tech. Co., Ltd has announced two strategic partnerships aimed at enhancing its digital transformation and service offerings in the insurance sector, focusing on integrating advanced technologies such as AI and blockchain into insurance workflows [1][8]. Partnership with Guangzhou HZIA - The Technical Services Cooperation Agreement with Guangzhou Hengzhun Insurance Appraisal Co., Ltd aims to optimize insurance claims adjusting through bespoke digital solutions, including AI image recognition and drone-based disaster assessment [2][3]. - This partnership is expected to create a unified platform that integrates YSX's after-sales network with Guangzhou HZIA's expertise, enhancing the claims process and supporting dynamic risk control systems [4]. Partnership with Tanbao Network - Xinjiang Yishengxin Network Technology Co. Ltd has entered a two-year Technical Cooperation Framework Agreement with Tanbao Network Technology, focusing on AI-driven solutions for insurance claims assessment and risk identification [2][5]. - The collaboration aims to leverage Tanbao Network's AI capabilities and Xinjiang Yishengxin's industry knowledge to develop digital models for insurance-related assets and explore new service offerings [6][7]. Management Commentary - The Chairman and CEO of YSX emphasized that these partnerships represent a significant advancement in the company's "Technology + Service" strategy, aiming to elevate service efficiency and client value in the insurance sector [8][9]. - The company anticipates that these collaborations will foster the widespread use of AI in insurance, creating new growth opportunities and propelling the insurtech sector into a new era of development [9].

Core Viewpoint - Aterian, Inc. is actively progressing in its Strategic Alternative Process aimed at maximizing shareholder value, with expectations for further updates in mid-April 2026 [2][4]. Group 1: Strategic Alternatives - The Board of Directors has authorized a formal process to evaluate strategic alternatives, which may include asset sales, company sales, business combinations, or mergers [3]. - Aterian is engaging with financial and legal advisors to explore a broad range of proposals that align with the goal of maximizing shareholder value [4][5]. Group 2: Company Overview - Aterian, Inc. is a consumer products company that builds and acquires e-commerce brands across various categories, including home appliances, health and wellness, and air quality devices [6]. - The company sells products through major online marketplaces such as Amazon, Walmart, and Target, as well as its own direct-to-consumer websites [6].

Core Insights - The successful integration of Palladyne AI's SwarmOS with Draganfly's drone systems marks a significant advancement towards next-generation defense applications [1][2] - This integration enables decentralized, real-time collaboration among drones, enhancing their operational capabilities in dynamic environments [3][4] Company Developments - Draganfly Inc. has completed a key milestone by testing SwarmOS across its drone components and validating it through flight simulation [2][5] - The integration allows drones to operate autonomously, making decisions and collaborating without centralized control, which is crucial for U.S. defense applications [3][5] Technological Innovations - The SwarmOS platform utilizes a Decentralized Edge Collaborative Autonomy (DECA) approach, enabling drones to independently perceive their environment and adapt to mission conditions [3][4] - This technology is designed to maintain operational effectiveness even in scenarios with degraded communications or asset loss [4] Market Context - The milestone aligns with the increasing demand for large-scale autonomous systems in U.S. defense initiatives, particularly in contested environments [5] - Draganfly is expanding its presence in defense applications, including support for U.S. Air Force Special Operations Command and various tactical drone platforms [6]

Core Viewpoint - Quantum BioPharma Ltd. announced the publication of a clinical trial demonstrating that its dietary supplement 'unbuzzd' significantly accelerates alcohol metabolism, reduces blood alcohol concentration (BAC), and alleviates symptoms of intoxication and hangover [1][7]. Clinical Trial Findings - The clinical trial was a double-blind, randomized, placebo-controlled study involving healthy participants aged 21 to 43, who consumed alcohol to achieve a BAC between 0.07% and 0.11% before taking either unbuzzd or a placebo [2]. - unbuzzd reduced BAC by more than 40% faster within the first 30 minutes compared to placebo, with continued acceleration observed over a four-hour period [5]. - Participants reported significant improvements in alertness within 30 minutes of consuming unbuzzd, outperforming placebo results [6]. - The supplement stabilized heart rate and blood pressure, which are typically elevated during alcohol intoxication, with these results being statistically significant [6]. - Participants experienced a statistically significant reduction in hangover symptoms, including a 67% reduction in headache severity at four and eight hours post-consumption [6]. Product Information - unbuzzd is a dietary supplement developed by a team of scientists at Quantum BioPharma, comprising a proprietary blend of vitamins and supplements [1][9]. - The product is available for purchase through its website and on Amazon, with various packaging options [10]. - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which markets unbuzzd, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will drop to 3% [12].

Group 1 - Jyske Realkredit A/S will list 4 new Covered Bonds (SDO) and 1 Mortgage Bond (RO) on 24 March 2026 [1] - The final terms for the bonds are included in the announcement and are part of the full prospectus [2] - The base prospectus for the bonds was previously disclosed and is available on Jyske Realkredit's website [2]